Researchers have shown that the enhanced ability of activated CLL cells to resist apoptosis is reliant on the activation of alternative BCL2 family members, such as BCL2A1 and BCL-XL, through the use of CD40 signaling and IL4 stimulation [19,20]. The gene discussed is CD40; the disease is B-cell chronic lymphocytic leukemia.